Search Results - t-cell+receptor

7 Results

Sort By:

T-Cell Immunotherapy that Targets Aggressive Epithelial Tumors

Abstract: Metastatic cancers cause up to 90% of cancer deaths, yet few treatment options exist for patients with metastatic disease. Adoptive transfer of T cells that express tumor-reactive T-cell receptors (TCRs) has been shown to mediate regression of metastatic cancers in some patients. Unfortunately, identification of antigens expressed solely...

Published: 4/8/2024 | Inventor(s): Sanja Stevanovic, Christian Hinrichs

Keywords(s): CT83, Immunotherapy, Kita-Kyushu Lung Cancer Antigen, KK-LC-1, T-Cell Receptor, TCR, Testis

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer

Abstract: Adoptive cell therapy (ACT) is a breakthrough form of cancer immunotherapy that utilizes autologous, antitumor T cells to attack tumors through recognition of tumor-specific mutations, or neoantigens. A major hurdle in the development of ACT is the exhausted phenotype exhibited by many neoantigen-specific T cells, which limits their efficacy...

Published: 4/8/2024 | Inventor(s): Sri Krishna, Zhiya Yu, Kenichi Hanada, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Krishna, Neoantigen, Rosenberg, T-Cell Receptor, TCR, Vaccine

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias

Abstract: CD20 is a protein expressed by wide ranges of lymphoid malignancies originating from B cells but not by indispensable normal tissues, making it an attractive target for therapies such as T-cell receptor (TCR) therapy. Current anti-CD20 therapeutics face a number of limitations. The most important limitation to current anti-CD20 therapies include...

Published: 8/14/2024 | Inventor(s): Kazusa Ishii, Christian Hinrichs

Keywords(s): Acute Lymphoblastic Leukemia, ALL, CD20, Chronic lymphocytic leukemia, CLL, Hinrichs, Ishii, NHL, Non-Hodgkin’s Lymphoma, Resistant B-lymphoid malignancies, T-Cell Receptor, TCR

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

A Method to Isolate Tumor Specific T-Cells or T-Cell Receptors from Peripheral Blood using In-vitro Stimulation of Memory T-Cells

Abstract: Adoptive cell transfer (ACT) and T-cell receptor (TCR) therapies use lymphocytes that target somatic mutations expressed by tumors cells to treat cancer patients. One of the challenges of these therapies is the identification and isolation of mutation-specific cells and TCRs. While neoantigen specific cells are relatively abundant in the tumor,...

Published: 4/8/2024 | Inventor(s): Gal Cafri, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer therapy, Immunotherapy, In-vitro Stimulation, IVS, Rosenberg, T-cell Isolation, T-Cell Receptor, TCR

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias

Abstract: CD22 is a protein expressed by normal B cells and B-lymphoid malignancies. Its limited tissue expression pattern makes it a safe antigen for targeted therapies, such as T-cell Receptor (TCR)-T cell therapy. CD22-targeting therapies already on the market, mainly antibody-immunotoxin conjugates and chimeric antigen receptors (CAR)-T cells, have...

Published: 8/14/2024 | Inventor(s): Kazusa Ishii, Christian Hinrichs

Keywords(s): Acute Lymphoblastic Leukemia, ALL, B cells, CD22, Cellular Immunotherapy, Chronic lymphocytic leukemia, CLL, Hinrichs, Ishii, NHL, Non-Hodgkin’s Lymphoma, Relapsed / refractory B-Lymphoid Malignancies, T-Cell Receptor, TCR

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology

HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation

Abstract: Mutation of amino acid 61of the neuroblastoma rat sarcoma viral oncogene homologue (NRAS) is a known driver of oncogenesis in melanoma. Glutamine (Q) to lysine (K) mutation at this position of NRAS is prevalent in approximately 10% of all melanoma cases and associated with aggressive tumors and low patient survival. Therefore, Q61K mutated...

Published: 4/8/2024 | Inventor(s): Paul Robbins, Steven Rosenberg, Gabriel Ivey, Almin Latani

Keywords(s): act, Adoptive Cell Transfer, HLA, Human Leukocyte Antigen, immuno-oncology, Immunotherapy, Neuroblastoma Rat Sarcoma Viral Oncogene, NRAS, Robbins, Rosenberg, T-Cell Receptor, TCR

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing

Cancer-reactive T cells from Peripheral Blood

Abstract: Adoptive cell therapy (ACT) using genetically engineered T-cell receptors (TCRs) is a promising cancer treatment. These TCRs target genetic mutations unique to patients and play an important role in tumor regression. However, mutation-reactive T-cells and their TCRs can be difficult to identify and isolate from patients. Therefore, we need...

Published: 4/8/2024 | Inventor(s): Alena Gros, Steven Rosenberg

Keywords(s): CANCER, Gros, Immunotherapy, mutation-reactive T-cells, Rosenberg, T-Cell Receptor, T-CELLS, TCR

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology